•  
  •  
  •  
  •  

2026-07-19 23:46:10

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Can Fin Homes Limited Delivers Strong Opening to FY27: Net Profit Rises 20% to ₹268 Crore Driven by Robust Disbursements
  • Punjab & Sind Bank Registers 23.05% Net Profit Surge in Q1 FY27 Powered by Robust Credit Growth and Improving Asset Quality
  • Bhansali Engineering Polymers Limited Marks Strong Start to FY27: Q1 Consolidated Net Profit Surges 42.9% to ₹65.60 Crore
  • Sangam India Ltd Reports Surge in Q1 FY27 Net Profit to ₹4,102 Lakhs
  • Rossari Biotech Limited Posts Steady Q1 FY27 Growth: Net Profit Rises to ₹350.95 Million

Keywords Selected:  PreApprovalInspection

Stock Report

  • Glenmark Pharmaceuticals Ltd update on USFDA PAI at Chhatrapati Sambhajinagar Facility
  • Closure of USFDA inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Lupin gets one observation from USFDA for Somerset, New Jersey manufacturing facility
  • Lupin gets 4 observations from USFDA from PAI at Pune Biotech facility
  • USFDA conducts product specific pre-approval inspection at Lupin Ltd's Aurangabad facility
  • Granules India Ltd receives 1 observation from USFDA for Chantilly facility
  • Gland Pharma Ltd receives EIR from US FDA for JNPC Facility, Visakhapatnam
  • Piramal Pharma Limited's Ahmedabad facility successfully completes USFDA Pre-Approval Inspection
  • Torrent Pharmaceuticals Ltd gets Form 483 with 5 observations for Indrad facility
  • Piramal Pharma Ltd gets Form 483 with 2 observations from USFDA for Lexington, USA facility
  • Torrent Pharmaceuticals Ltd gets Form 483 from USFDA after Pre-Approval Inspection for Bileshwarpura facility
  • Bajaj Healthcare Ltd receives EIR from USFDA for API manufacturing facility in Savli
  • Aurobindo Pharma Ltd's Unit 7 completes USFDA PAI successfully
  • US FDA Inspection at Pashmylaram Facility, Hyderabad of Gland Pharma Ltd
  • Zydus Lifesciences Ltd gets 3 observations from USFDA for Pharmex, Ahmedabad facility
  • Bliss GVS Pharma Ltd gets 3 minor observations from USFDA for Palghar unit
  • USFDA Pre-Approval Inspection of Oral Oncology Manufacturing facility, Gujarat
  • Granules India Ltd gets 3 observations from USFDA for Gagillapur facility
  • Alembic Pharmaceuticals gets 5 observations from USFDA for Solid Oral Formulation Facility (F-4) at Jarod
  • Bajaj Healthcare Ltd announces successful completion of USFDA pre approval inspection at API facility
  • Syngene International Ltd update on USFDA Inspection of Biologics facility
  • Laurus Labs Ltd gets one observation from USFDA for Pre-Approval Inspection
  • Cipla Ltd receives EIR for Indore plant
  • US FDA inspection at Alkem's manufacturing facility located at St. Louis, USA

Latest Post

  • Can Fin Homes Limited Delivers Strong Opening to FY27: Net Profit Rises 20% to ₹268 Crore Driven by Robust Disbursements
  • Punjab & Sind Bank Registers 23.05% Net Profit Surge in Q1 FY27 Powered by Robust Credit Growth and Improving Asset Quality
  • Bhansali Engineering Polymers Limited Marks Strong Start to FY27: Q1 Consolidated Net Profit Surges 42.9% to ₹65.60 Crore
  • Sangam India Ltd Reports Surge in Q1 FY27 Net Profit to ₹4,102 Lakhs
  • Rossari Biotech Limited Posts Steady Q1 FY27 Growth: Net Profit Rises to ₹350.95 Million


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025